167 related articles for article (PubMed ID: 38252908)
21. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Yoo SY; Mathias M; Han H; Seebach F; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2023 Nov; 24(11):1196-1205. PubMed ID: 37875144
[TBL] [Abstract][Full Text] [Related]
22. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
Hanania HL; Lewis DJ
J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
[TBL] [Abstract][Full Text] [Related]
23. Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Swanson L; Kassab I; Tsung I; Worden FP; Fontana RJ
Immunotherapy; 2022 Apr; 14(6):409-418. PubMed ID: 35232282
[TBL] [Abstract][Full Text] [Related]
24. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
25. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
26. Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature.
Lu Z; Afzal M; Shirai K
Transpl Immunol; 2023 Dec; 81():101932. PubMed ID: 37734447
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
[TBL] [Abstract][Full Text] [Related]
28. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
29. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
Front Oncol; 2021; 11():691980. PubMed ID: 34540666
[TBL] [Abstract][Full Text] [Related]
32. Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.
Orte Cano C; Van Meerhaeghe T; Tannous J; Lienard D; Van Gestel D; Cuylits N; Luce S; Carlot S; Le Moine A; Aspeslagh S; Del Marmol V
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():53-58. PubMed ID: 34855244
[TBL] [Abstract][Full Text] [Related]
33. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
34. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers.
Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S
J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
[TBL] [Abstract][Full Text] [Related]
36. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
Lewis KD; Peris K; Sekulic A; Stratigos AJ; Dunn L; Eroglu Z; Chang ALS; Migden MR; Yoo SY; Mohan K; Coates E; Okoye E; Bowler T; Baurain JF; Bechter O; Hauschild A; Butler MO; Hernandez-Aya L; Licitra L; Neves RI; Ruiz ES; Seebach F; Lowy I; Goncalves P; Fury MG
Ann Oncol; 2024 Feb; 35(2):221-228. PubMed ID: 38072158
[TBL] [Abstract][Full Text] [Related]
37. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies.
Wang BC; Xiao BY; Kuang BH; Lin GH
Dermatol Ther; 2022 Sep; 35(9):e15715. PubMed ID: 35821497
[TBL] [Abstract][Full Text] [Related]
39. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
40. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]